Dienogest - Endometriosis

You are here : Home > Formulary Search > Dienogest - Endometriosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue

Formulations :

Not Specified

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

SPC

Restrictions / Comments :

Important

To be initiated and first 6 months treatment to be supplied by a specialist

Documentation

Guidelines (Local)

Dienogest for the management of pain in endometriosis - BLUE information sheet - July 2022.pdf

Evidence Review

Dienogest for endometriosis management - Evidence review - November 2021.pdf

PAD Profile

ChemicalSubstance :

Dienogest

Indication :

Endometriosis

Group Name :

Keywords :

Fibroids

Brand Names Include :

Zalkya, Dimetrum

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Committee Recommendations (1)

06 Jul 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agreed dienogest as a treatment option, after the optimisation of other hormonal treatments, for the management of endometriosis and associated pain symptoms.

Dienogest will be given a BLUE (with information sheet) traffic light status. NOTE added in January 2025, treatment to be initiated and first 6 months treatment to be supplied by a specialist.

Other Indications

Below are listed other indications that Dienogest is used to treat.

No records returned.

Other Drugs

Below are listed other drugs that are used to treat Endometriosis.